COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP) TREATMENT DRUGS MARKET ANALYSIS

Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, by Drug Class (Pleuromutilin Antibiotic, Cephalosporin, Glycylcycline, Oxazolidinone, Ketolide, and Others), by Dose Form (Solution and Tablet), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Nov 2020
Code : CMI4269
Pages :188
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

However, inappropriate treatment due to incorrect identification of pathogen contribute to the limited use of current drugs in the management of CABP. For instance, according to an article published in November 2019 in the National Center for Biotechnology Information (NCBI), the presence of multiple pathogens in patients leads to incorrect selection of initial antibiotic, which may affect the mortality outcome in CABP. Such inappropriate medication are expected to hamper the market growth.

Restraints & Challenges: